March 27 (Reuters) - Par Pharmaceutical Cos Inc said the United States Department of Justice is currently investigating promotional practices of its unit in the sales of its appetite-stimulant Megace.
PURPOSE: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback